The Latest Breaking News from Obesity

While the nutritional needs of GLP-1 users are not drastically different from the general population, according to a dietician, the key distinction lies in reduced food intake

The stronger Wegovy dose could see more than 20 per cent weight loss in patients with obesity

People who use weight-loss drugs can rapidly regain weight after stopping treatment, according to a new study

In today’s newsletter: A new study shows that people don’t just regain weight after stopping GLP-1 drugs, they see other positive health markers reverse – leading to questions about long-term impacts and solutions

Weight-loss injections, like Wegovy and Mounjaro, have been hailed as gamechangers. In clinical trials, people lost an average of 15%-20% of their body weight – results that seemed almost miraculous compared to traditional diet and exercise programmes.

Many taking weight loss drugs could be at risk of ‘replacing one set of health problems with another’, academics warned

The vast majority of people taking Wegovy and Mounjaro pay privately owing to restrictions on who can access the medicines via the NHS.

For millions of people, weight-loss injections such as Wegovy and Mounjaro have felt like a breakthrough that finally makes eating less feel easier. In a few short years, these so-called GLP-1 drugs have reshaped how obesity is treated and how people think about appetite and willpower. But their success raises…

A loophole in the ban means companies can still advertise brand names, which experts argue leaves children no better protected